Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
22 April 2022
A Correction to this paper has been published: https://doi.org/10.1038/s41587-022-01322-1
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Diabetes cell therapies take evasive action. Nat Biotechnol 40, 291–295 (2022). https://doi.org/10.1038/s41587-022-01246-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01246-w
This article is cited by
-
Inflammation-induced subcutaneous neovascularization for the long-term survival of encapsulated islets without immunosuppression
Nature Biomedical Engineering (2023)
-
Challenges with Cell-based Therapies for Type 1 Diabetes Mellitus
Stem Cell Reviews and Reports (2023)
-
Engineering the next generation of cell-based therapeutics
Nature Reviews Drug Discovery (2022)